Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | CA7 | P43166 | 4/20 | 0.67 |
| ▸ | CA9 | Q16790 | 4/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.67 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.67 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MYC | P01106 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11690819 | 0.86 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31258832 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1367028 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2708451 | 0.84 | SLC6A4 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30301996 | 0.84 | SLC6A4 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL523258 | 0.82 | CES2 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14012584 | 0.82 | CES2 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25045978 | 0.81 | GAA (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1097161 | 0.81 | NPC1 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23607068 | 0.81 | SLC6A4 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115470-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | SA, GIVAUDAN (CH) | 2024-04-11 | — | — | US | claimed |
| EP-4259082-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | Givaudan SA (CH) | 2023-10-18 | — | — | EP | claimed |
| WO-2022122836-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | GIVAUDAN SA (CH) | 2022-06-16 | — | — | WO | claimed |
| CN-107235978-B | A kind of preparation method of ABT-199 intermediate | 上海泓博智源医药股份有限公司 | 2019-05-21 | — | — | CN | claimed |
| CN-107235978-A | A kind of preparation method of the intermediates of ABT 199 | 上海泓博智源医药股份有限公司 | 2017-10-10 | — | — | CN | claimed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD (AU) | 2026-05-05 | — | — | US | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250377364-A1 | REAGENT, METHOD, AND DEVICE FOR DETECTING ALBUMIN | NEC CORPORATION (JP) | 2025-12-11 | — | — | US | disclosed |
| EP-4638460-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2025-10-29 | — | — | EP | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-20040058959-A1 | Substituted carboxamides | HERRON DAVID KENT (US) | 2004-03-25 | — | — | US | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1379506-A2 | SUBSTITUTED CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1373248-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074763-A9 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002074763-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002064567-A2 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250377364-A1 | REAGENT, METHOD, AND DEVICE FOR DETECTING ALBUMIN | ALB, TTR, MTTP | CA12 367/4885CA1 1488/4885CA2 3341/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | CA12 1371/4885CA1 436/4885CA2 323/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | CA12 1419/4885CA1 1434/4885CA2 2353/4885 |
| US-20240115470-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | KDM5B, FOSB, KDM2B | CA12 2279/4885CA1 3577/4885CA2 2648/4885 |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, IRF3 | CA12 3837/4885CA1 3784/4885CA2 2504/4885 |
| US-20040058959-A1 | Substituted carboxamides | F11, F12, TFPI | CA12 374/4885CA1 852/4885CA2 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.